Development of an automated chemiluminescence enzyme immunoassay for the measurement of soluble C-type lectin-like receptor 2 (sCLEC-2) and molecular forms of sCLEC-2 measured in patient plasma DOI Creative Commons
Masahide Kawamura,

M Ueda,

S. Matsushita

et al.

Platelets, Journal Year: 2024, Volume and Issue: 35(1)

Published: Oct. 30, 2024

Soluble CLEC-2 is anticipated to have various clinical applications as a novel biomarker for in vivo platelet activation, assessable using plasma obtained through routine sampling procedures. While sCLEC-2 has been measured ELISA, we developed highly sensitive chemiluminescence enzyme immunoassay (CLEIA) reagent that can yield results approximately 19 minutes. This study aims assess its fundamental performance and explore the molecular forms of patient samples. We examined sensitivity, precision, linearity, influence endogenous substances, residual platelets, well correlation with ELISA method, CLEIA reagent. The method demonstrated sufficient sensitivity levels observed healthy donors, basic was satisfactory. It exhibited strong previously described reference ranges did not significantly differ from data. range males higher than females. Since it known exists shed form microparticle form, investigated by vitro-activated platelets patients' gel filtration. considered shows stronger reactivity compared form. Studies filtration samples also suggest being primarily measured. exhibits robust promising applications.

Language: Английский

Thromboinflammation in acute injury: infections, heatstroke, and trauma DOI Creative Commons
Toshiaki Iba, Julie Helms, Marcel Levi

et al.

Journal of Thrombosis and Haemostasis, Journal Year: 2023, Volume and Issue: 22(1), P. 7 - 22

Published: Aug. 3, 2023

Language: Английский

Citations

39
2025 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles DOI Creative Commons
Emmanuel J. Favaloro

Seminars in Thrombosis and Hemostasis, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Welcome to the latest of our Eberhard F Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, publisher Seminars Thrombosis and Hemostasis (STH), has created "Eberhard Excellence Awards" honor ([Fig. recognition his contribution this field journal that he both founded steered for over three decades. These awards began 2009, under two categories, "Most Popular Article "Young Investigator Awards." Accordingly, 2025 represents 17 years presentations 1]). Current details conditions can be summarized as:

Language: Английский

Citations

1
Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations DOI
Toshiaki Iba, Marcel Levi, Jecko Thachil

et al.

Seminars in Thrombosis and Hemostasis, Journal Year: 2022, Volume and Issue: 48(08), P. 978 - 987

Published: Sept. 13, 2022

Abstract Disseminated intravascular coagulation (DIC) has been understood as a consumptive coagulopathy. However, impaired hemostasis is component of DIC that occurs in progressive manner. The critical concept systemic activation with vascular endothelial damage. the dynamic coagulation/fibrinolysis disorder can proceed from compensated to decompensated phases, and not simply hemostasis, misunderstanding continues evoke confusion among clinicians. step disease progression important monitor over time. Impaired microcirculation subsequent organ failure due pathologic microthrombi formation are pathophysiologies sepsis-associated DIC. factor depletion hemodilution, shock, hyperfibrinolysis trauma-associated Overt-DIC diagnostic criteria have used clinically for more than 20 years but may be adequate detect phase DIC, different underlying causes, there no “one-size-fits-all criteria.” Individualized heterogeneous conditions continue proposed facilitate diagnosis. We believe future research will provide therapeutics using new criteria. Finally, also classified either acute or chronic, results short time requires urgent management. In this review, we examine advances

Language: Английский

Citations

37
Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part IV DOI Open Access
Emmanuel J. Favaloro, Leonardo Pasalic, Giuseppe Lippi

et al.

Seminars in Thrombosis and Hemostasis, Journal Year: 2023, Volume and Issue: 49(01), P. 003 - 008

Published: Jan. 5, 2023

Welcome to another issue of Seminars in Thrombosis and Hemostasis (STH), published under the "banner" "Maintaining hemostasis preventing thrombosis coronavirus disease 2019 (COVID-19)," this being Part IV, or fourth such volume. The first three issues were, respectively, 2020,[1] 2021,[2] 2022,[3] proved very popular with STH readership. COVID-19 is caused by severe acute respiratory syndrome 2 (SARS-CoV-2). Believed originate from Wuhan City China, reported case November 2019, at time writing, there were over 630 million cases worldwide 6.5 attributable deaths, thus including it among 10 most deadly pandemics throughout recent human history.[4]

Language: Английский

Citations

17
COVID-19 and the Concept of Thrombo-Inflammation: Review of the Relationship between Immune Response, Endothelium and Coagulation DOI Open Access
Emmanuel de Maistre, Philippe Savard, Pierre-Grégoire Guinot

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(23), P. 7245 - 7245

Published: Nov. 23, 2023

COVID-19, caused by the SARS-CoV-2 virus, has revealed a complex interplay between inflammation and coagulation, leading to emergence of concept thrombo-inflammation. This recognizes that COVID-19 is not solely respiratory illness, but systemic disease with significant vascular hematological components. associated an unusual prothrombotic state, intense endothelial activation vasculopathy, cytokine storm, complement system hypercoagulability state (the platelets coagulation cascade, impaired fibrinolysis). The aim this review discuss different pathological pathways described in lead thromboembolic events. Widespread vaccination post-COVID-19 immunization allows control over severity pandemic. A better understanding pathophysiology can improve management frail patients who are hospitalized intensive care units.

Language: Английский

Citations

14
COVID-19: Not a thrombotic disease but a thromboinflammatory disease DOI Creative Commons
Shu He,

Margareta Blombäck,

Håkan Wallén

et al.

Upsala Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 129

Published: Jan. 22, 2024

While Coronavirus Disease in 2019 (COVID-19) may no longer be classified as a global public health emergency, it still poses significant risk at least due to its association with thrombotic events. This study aims reaffirm our previous hypothesis that COVID-19 is fundamentally disease. To accomplish this, we have undertaken an extensive literature review focused on assessing the comprehensive impact of entire hemostatic system. Our analysis revealed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection significantly enhances initiation thrombin generation. However, noteworthy generation modulated by specific anticoagulants present patients’ plasma. Consequently, higher levels fibrinogen appear play more pivotal role promoting coagulation COVID-19, opposed Furthermore, viral can stimulate platelet activation either through widespread dissemination from lungs other organs or localized effects platelets themselves. An imbalance between Von Willebrand Factor (VWF) and ADAMTS-13 also contributes exaggerated response this disease, addition elevated D-dimer levels, coupled increase fibrin viscoelasticity. paradoxical phenotype has been identified ‘fibrinolysis shutdown’. clarify pathogenesis underlying these disorders examined published data, tracing reaction process relevant proteins cells, ACE2-dependent invasion, induced tissue inflammation, endothelial injury, innate immune responses, occurrence We therefrom understand should viewed disease solely based abnormalities clot formation proteolysis. Instead, regarded thromboinflammatory disorder, incorporating both classical elements cellular inflammation their intricate interactions coagulopathy.

Language: Английский

Citations

6
2024 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles DOI Creative Commons
Emmanuel J. Favaloro

Seminars in Thrombosis and Hemostasis, Journal Year: 2024, Volume and Issue: 50(07), P. 919 - 932

Published: March 8, 2024

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, publisher Seminars Thrombosis & Hemostasis (STH), has created "Eberhard Excellence and Awards" honor ([Fig. recognition his contribution this field journal that he both founded steered for over three decades. These awards began 2009, under two categories, "Most Popular Article "Young Investigator Awards." Accordingly, 2024 represents 16 years presentations 1]). Current details conditions can be summarized as:

Language: Английский

Citations

5
COVID-19, Blood Lipid Changes, and Thrombosis DOI Creative Commons

Akhlaq A. Farooqui,

Tahira Farooqui,

Grace Y. Sun

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(4), P. 1181 - 1181

Published: April 15, 2023

Although there is increasing evidence that oxidative stress and inflammation induced by COVID-19 may contribute to increased risk severity of thromboses, the underlying mechanism(s) remain be understood. The purpose this review highlight role blood lipids in association with thrombosis events observed patients. Among different types phospholipases A2 target cell membrane phospholipids, focus on inflammatory secretory phospholipase IIA (sPLA2-IIA), which associated COVID-19. Analysis indicates sPLA2-IIA levels together eicosanoids sera COVID sPLA2 could metabolise phospholipids platelets, erythrocytes, endothelial cells produce arachidonic acid (ARA) lysophospholipids. Arachidonic platelets metabolised prostaglandin H2 thromboxane A2, known for their pro-coagulation vasoconstrictive properties. Lysophospholipids, such as lysophosphatidylcholine, autotaxin (ATX) further converted lysophosphatidic (LPA). Increased ATX has been found serum patients COVID-19, LPA recently induce NETosis, a clotting mechanism triggered release extracellular fibres from neutrophils key feature hypercoagulable state. PLA2 also catalyse formation platelet activating factor (PAF) ether phospholipids. Many above lipid mediators are Together, findings analyses suggest an important metabolites COVID-19-associated coagulopathy (CAC).

Language: Английский

Citations

13
What Role Does Microthrombosis Play in Long COVID? DOI
Toshiaki Iba, Jean M. Connors, Jerrold H. Levy

et al.

Seminars in Thrombosis and Hemostasis, Journal Year: 2023, Volume and Issue: 50(04), P. 527 - 536

Published: Sept. 25, 2023

Abstract Soon after the outbreak of coronavirus disease 2019 (COVID-19), unexplained sustained fatigue, cognitive disturbance, and muscle ache/weakness were reported in patients who had recovered from acute COVID-19 infection. This abnormal condition has been recognized as “long COVID (postacute sequelae [PASC])” with a prevalence estimated to be 10 20% convalescent patients. Although pathophysiology PASC studied, exact mechanism remains obscure. Microclots circulation can represent one possible causes PASC. hypercoagulability thrombosis are critical mechanisms COVID-19, recent studies have that thromboinflammation continues some patients, even virus cleared. Viral spike proteins RNA detected months recovered, findings may responsible for persistent development microclots. Despite this theory, long-term results anticoagulation, antiplatelet therapy, vascular endothelial protection inconsistent, could not always show beneficial treatment effects. In summary, reflects heterogeneous condition, microclots cannot explain all presenting symptoms. After clarification pathomechanisms each symptom, symptom- or biomarker-based stratified approach should considered future studies.

Language: Английский

Citations

13
Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal DOI Creative Commons
Francesco Samarelli, Giovanni Graziano, Nicola Gambacorta

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(3), P. 450 - 450

Published: March 14, 2024

People affected by COVID-19 are exposed to, among others, abnormal clotting and endothelial dysfunction, which may result in deep vein thrombosis, cerebrovascular disorders, ischemic non-ischemic heart diseases, to mention a few. Treatments for include antiplatelet (e.g., aspirin, clopidogrel) anticoagulant agents, but their impact on morbidity mortality has not been proven. In addition, due viremia-associated interconnected prothrombotic proinflammatory events, anti-inflammatory drugs have also investigated ability mitigate against immune dysregulation the cytokine storm. By retrieving patent literature published last two years, small molecules patented long-COVID-related blood hematological complications herein examined, along with supporting evidence from preclinical clinical studies. An overview of main features therapeutic potentials is provided thromboxane receptor antagonist ramatroban, pan-caspase inhibitor emricasan, sodium–hydrogen antiporter 1 (NHE-1) rimeporide, as well natural polyphenolic compounds.

Language: Английский

Citations

4